CD34 selection as a stem cell purging strategy for neuroblastoma: Preclinical and clinical studies

Abstract

These data show that purging of NB from PBPC specimens using CD34 selection is feasible, yielding infused products that are negative at the level of ICC but often positive at the level of RT-PCR.

Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant

“…All patients had previously untreated high-risk neuroblastoma as defined by age older than 1 year, INSS stage 4 disease or INSS stage 3 disease with MYCN amplification, and/or unfavorable Shimada histopathology. The treatment regimen for this patient population has been previously reported [11][12][13]. Briefly, all patients received 5 cycles of induction chemotherapy, surgery, and radiation to the primary site.…”

Medulloblastoma Simulating Acute Myeloid Leukemia: Case Report With a Review of “Myeloid Antigen” Expression in Nonhematopoietic Tissues and Tumors

“…A number of CD34 antibodies are available, and there has been debate regarding antibody specificity for stem cell purification in patients with neuroblastoma, because some cross reactivity using specific antibodies has been demonstrated with this type of neuroectodermal tumor. 33,34 Although CD34 was positive by flow cytometry in our case, immunohistochemistry was negative, a finding that may be due to lesser sensitivity of immunohistochemistry or differing reactivity of antibodies from 2 manufacturers. Regardless, it seems that CD34 staining may be seen by flow cytometry in routine diagnostic material in at least rare patients with tumor metastatic to bone marrow.…”

Autologous and Allogeneic Cellular Therapies for High-risk Pediatric Solid Tumors

“…Concerns have indeed been raised that some neuroblastoma cells may express either CD34, or surface epitopes cross-reactive with the anti-CD34 monoclonal antibodies necessary for the selection process[67–68]. Our data have not confirmed this hypothesis[69], and we, along with others, have used CD34 selection as a purging technique for PBSC products in the clinical setting[70]. …”